FTC announces final order on AbbVie/Allergan merger with conditions

The U.S. Federal Trade Commission (FTC) has voted 3-1-1 approving a final order settling charges that AbbVie’s (ABBV +0.1%) $63B takeover of Allergan would violate federal antitrust law.

The complaint, filed in May, claimed that the tie-up would likely harm current competition in the exocrine pancreatic insufficiency (EPI) treatment market and future competition in IL-23 inhibitors.

The final order requires the companies to divest Allergan’s EPI meds Zenpep (pancrelipase) and Viokase (pancrelipase tablets, powder) to Nestlé S.A. (OTCPK:NSRGY) and Allergan’s IL-23 inhibitor brazikumab to AstraZeneca (AZN -1.3%).

https://seekingalpha.com/news/3611840-ftc-announces-final-order-on-abbvie-allergan-merger-conditions